The race against the clock defines organ transplantation. Once a liver leaves a donor’s body, degradation begins immediately. Traditional cold storage buys time but does little to halt cellular decay. A new study reveals that machine perfusion does more than just preserve organs; it actively reverses their biological age. Researchers at Mass General Brigham found that livers treated with nutrient-rich, oxygenated fluids on perfusion machines appeared significantly younger at a molecular level than those kept on ice.
Heidi Yeh, who led the work, described the results as striking. The team used epigenetic “aging clocks” to measure chemical marks on DNA and gene expression patterns in donated livers. In a cohort of 103 donors, machine-perfused livers showed a biological age roughly 30% lower than chronologically younger livers stored via traditional methods. Alban Longchamp, a transplant surgeon involved in the study, noted that pumping organs at 34 degrees Celsius with oxygen essentially reversed biological aging. This molecular rejuvenation persisted even after the organs were transplanted and subjected to the stress of re-establishing blood flow.
This finding offers a mechanistic explanation for why perfused organs often have better clinical outcomes. It suggests the technology repairs cellular damage rather than merely pausing it. Jesse Poganik, a coauthor from Brigham and Women’s Hospital, sees this as a pathway to improve organ utilization rates. If we can reliably assess and repair organs that might otherwise be discarded, the transplant waiting list could shrink. The study implies that biological age is a more accurate predictor of organ health than the donor’s chronological age.
However, the solution comes with a steep price tag. In the US, perfusion costs between $80,000 and $100,000 per organ. Nathanael Raschzok, a transplant surgeon at Charité Universitätsmedizin Berlin not involved in the study, called the work impressive but raised practical concerns. He questioned whether the effect holds for donors in their 80s and suggested that understanding the molecular mechanism could lead to cheaper drug-based therapies. Until then, hospitals must weigh the high cost of perfusion against the tangible benefit of a biologically younger graft.
